Citation for published version:
Bailey, SJ, Almatroudi, A & Kouris, A 2017, 'Tianeptine: An atypical antidepressant with multimodal
pharmacology', Current Psychopharmacology, vol. 6, no. 2, pp. 94-110.
https://doi.org/10.2174/2211556006666170525154616
DOI:
10.2174/2211556006666170525154616
Publication date:
2017
Document Version
Peer reviewed version
Link to publication
The final publication is available at Bentham Science via https://doi.org/10.2174/2211556006666170525154616
University of Bath
Alternative formats
If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Aug. 2022
1
Tianeptine: an atypical antidepressant with multimodal pharmacology
*Sarah J. Bailey, Abdulrahman Almatroudi and Andreas Kouris
Department of Pharmacy and Pharmacology, University of Bath, Claverton Down,
Bath BA2 7AY, UK.
Corresponding author:
Dr Sarah Bailey
Department of Pharmacy and Pharmacology
University of Bath
Claverton Down
Bath
BA2 7AY
S.Bailey@bath.ac.uk
TEL: 01225 386842
FAX: 01225 386114
KEY WORDS: depression, anxiety, serotonin, glutamate, -opioid receptor, gender, mTOR
CONFLICT OF INTEREST:
No funding was provided for this study. None of the authors have any conflict of interest.
AK was a pharmacology undergraduate; AA was a PhD student funded by the
Government of Saudi Arabia; all authors worked in the Department of Pharmacy and
Pharmacology at the University of Bath.
ACKNOWLEDGEMENTS: All authors contributed substantially to the research, drafting
and revision of the manuscript. No other persons were involved in the preparation of the
manuscript.
2
Abstract
Background: Tianeptine is an atypical antidepressant marketed as Stablon since the late
1980’s. While chemically very similar to tricyclic antidepressants, tianeptine was thought to
have the apparently paradoxical mechanism of action of enhancing serotonin reuptake.
However, recent data highlight a multimodal pharmacology for tianeptine including actions
at glutamatergic synapses (inhibiting NMDA receptors and an indirect effect on AMPA
receptors) coupled with agonist effects at mu opioid receptors (-receptors). Objective:
We have reviewed clinical and preclinical data for tianeptine to provide a comprehensive
study of its pharmacology. Results: Clinical trials show that tianeptine is at least as
efficacious as first-line antidepressant treatments, with improved tolerability as it is
significantly less prone to disrupting the patient's normal functionality. Tianeptine appears
more efficacious in males than females, although these gender-specific differences may
be accounted for by pharmacokinetics. Preclinical data suggest that the ability to stabilise
glutamatergic neurotransmission may underlie tianeptine’s ability to improve cognitive
function and anxiety-related symptoms. Alternatively, -receptor activation of the mTOR
signalling pathway could lead tianeptine to be a fast-acting antidepressant. Agonist actions
at -receptors could also explain the potential abuse liability and dependence issues seen
with high dose tianeptine. Conclusion: Tianeptine itself is off patent, but it still holds much
promise as an experimental tool yielding valuable insights into the molecular mechanisms
underlying depression.
3
1. Introduction
Major depressive disorder (MDD) is a highly pervasive disorder, characterised by
persistent low mood, low self-esteem and anhedonia. In the UK, depression affects 4
million adults, 8.4% of the total population and has been linked with poor health, significant
comorbidity and mortality [1-3]. MDD, therefore, is characterised as a severely debilitating
disease with a major impact not only on a person's quality of life but can also place a
massive financial strain on a country’s healthcare system.
The prevalence of the monoamine hypothesis as a causative factor of depression has
driven the development of therapies that aim at restoring the neurochemical imbalance in
noradrenaline, serotonin and dopamine. The principle classes of antidepressants utilised
to restore this neurochemical alteration are the monoamine oxidase inhibitors (MAOIs),
tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs) and
serotonin noradrenaline reuptake inhibitors (SNRIs).All four classes of antidepressants
have proven to be catalysts by dramatically improving the quality of life of depressed
patients [4]. These agents, however, are associated with limitations in their onset of action,
efficacy, tolerability and safety. These antidepressants have a delayed time of onset as
they usually take four to six weeks to exhibit a therapeutic benefit [5]. Problems with the
efficacy of antidepressant therapy include drug resistance where between one and two-
thirds of patients will not respond to the first antidepressant prescribed and 15 to 33
percent will not respond to multiple interventions [6-7]. In terms of tolerability,
antidepressants that interfere with the serotonin system can lead to emotional detachment
[8] and interfere with normal sexual function [9] thus discouraging patients from complying
with therapy. Finally, in terms of safety, even though antidepressants are generally
regarded as safe, they have been associated with life-threatening side-effects including
cardiovascular effects [10] and, controversially, an increased risk of suicide [11-12].
Tianeptine is an atypical antidepressant with a novel mechanism of action. Marketed since
the late 1980’s as Stablon, tianeptine is available in Europe, Latin America, and Asia as a
treatment for MDD although it is not available in the UK or North America [13]. Here we
review the evidence demonstrating the clinical efficacy and potential advantages of
tianeptine as an antidepressant, alongside recent advances in understanding its unique
4
multimodal psychopharmacology which could shed light on the molecular mechanisms
underlying depression.
2. Clinical Efficacy of Tianeptine
We have attempted a comprehensive review of all the accessible clinical trial information
on tianeptine and our findings are summarized in Table 1. The clinical efficacy of
tianeptine has been assessed in a vast number of clinical trials, including two small term
placebo controlled double blind studies; their purpose being the assessment of the efficacy
of tianeptine in adult patients of both genders with unipolar or bipolar depression [14-15].
Treatment of both male and female patients (n=129) with tianeptine (37.5 mg/day) for 42
days resulted in a reduction in the Montgomery-Asberg depression scale (MADRS) of
62.3% as compared to placebo (48.5%) [14].The efficacy of tianeptine has also been
shown in long-term studies to assess remission and relapse. In one study, 286 adult
patients of both genders were treated with tianeptine for 6 weeks [16]. The patients that
responded to tianeptine (n=185) were then randomly assigned to tianeptine (37.5 mg/day,
n=111) or placebo (n=74) for up to 18 months and were assessed for their rate of relapse
and reoccurrence by using the Hamilton depression rating scale and the CGI scale [16].
The results of the trial revealed that by the 18-month timepoint, in tianeptine treated
patients, the rate of relapse and reoccurrence was lower (16%) compared to placebo
(36%) [16].
Most of the clinical studies investigating the antidepressant efficacy of tianeptine have
compared its efficacy in parallel with other classes of antidepressants. In double-blind
studies of 4-24 weeks duration, tianeptine (37.5mg/day) showed similar efficacy as the
TCAs amitriptyline (75 mg/day) [17-18] and imipramine (150 mg/d) [15], the atypical
antidepressant mianserin (60mg/day) [19] but also the SSRIs fluoxetine (20mg/day) [20]
and paroxetine (20mg/day) [21]. Additionally, in a meta-analysis comparison with SSRIs,
tianeptine was shown to be just as efficacious during the same treatment period of 6
weeks [22].